Cost-effective interventions are often implemented slowly and suboptimally in clinical practice. In such situations, a range of implementation activities may be considered to increase uptake. A framework is proposed to use costeffectiveness analysis to inform decisions on how best to invest in implementation activities. This framework addresses 2 key issues: 1) how to account for changes in utilization in the future in the absence of implementation activities; and 2) how to prioritize implementation efforts between subgroups. A case study demonstrates the framework's application: novel oral anticoagulants (NOACs) for the prevention of stroke in the National Health Service in England and Wales. The results suggest that there is value in additional implementation activities to improve uptake of NOACs, particularly in targeting patients with average or poor warfarin control. At a cost-effectiveness threshold of £20,000 per quality-adjusted life-year (QALY) gained, additional investment in an educational activity that increases the utilization of NOACs by 5% in all patients currently taking warfarin generates an additional 254 QALYs, compared with 973 QALYs in the subgroup with average to poor warfarin control. However, greater value could be achieved with higher uptake of anticoagulation more generally: switching 5% of patients who are potentially eligible for anticoagulation but are currently receiving no treatment or are using aspirin would generate an additional 4990 QALYs. This work can help health services make decisions on investment at different points of the care pathway or across disease areas in a manner consistent with the value assessment of new interventions.
Cost-effective interventions are often implemented slowly and suboptimally in clinical practice. In such situations, a range of implementation activities may be considered to increase uptake. A framework is proposed to use costeffectiveness analysis to inform decisions on how best to invest in implementation activities. This framework addresses 2 key issues: 1) how to account for changes in utilization in the future in the absence of implementation activities; and 2) how to prioritize implementation efforts between subgroups. A case study demonstrates the framework's application: novel oral anticoagulants (NOACs) for the prevention of stroke in the National Health Service in England and Wales. The results suggest that there is value in additional implementation activities to improve uptake of NOACs, particularly in targeting patients with average or poor warfarin control. At a cost-effectiveness threshold of £20,000 per quality-adjusted life-year (QALY) gained, additional investment in an educational activity that increases the utilization of NOACs by 5% in all patients currently taking warfarin generates an additional 254 QALYs, compared with 973 QALYs in the subgroup with average to poor warfarin control. However, greater value could be achieved with higher uptake of anticoagulation more generally: switching 5% of patients who are potentially eligible for anticoagulation but are currently receiving no treatment or are using aspirin would generate an additional 4990 QALYs. This work can help health services make decisions on investment at different points of the care pathway or across disease areas in a manner consistent with the value assessment of new interventions. Key words: resource allocation; cost utility analysis; efficiency; clinical practice guidelines; technology assessment. (Med Decis Making 2017; 37:148-161) T he utilization of interventions that have been recommended by health systems is variable. 1, 2 Therefore, patients and systems in general do not attain the full value that these interventions offer. In the UK National Health Service (NHS), for example, implementation of guidance for prescription pharmaceuticals from the National Institute of Health and Care Excellence (NICE) can be limited, despite the requirement of mandatory funding and inclusion in hospital formularies. 1, 3, 4 Implementation of costeffective interventions can be encouraged with activities that address the barriers to uptake and promote their utilization. These activities can include audits and feedback, education and training, decision support systems, and outreach activities. 5 Implementation activities are complex interventions in that they attempt to affect behaviors and different groups of individuals, including health organizations, clinicians, and patients. 6 Despite their complex nature, however, implementation activities should be evaluated in a consistent manner to other health care interventions, given that they are competing for resources from the same budget. In other words, the benefits of implementation activities should be compared with their opportunity costs, which are the benefits that could be achieved from using these resources for other purposes.
This article outlines a framework, which extends existing approaches reported in the literature 7, 8 to assess of the value of implementation. The framework is then applied to a case study of novel oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation. NOACs are an example of an intervention that has been recommended by NICE through their technology appraisal process, but for which subsequent uptake is variable and remains lower than anticipated. 9 The framework and accompanying analyses aim to determine the value of additional implementation activities to increase utilization of NOACs beyond that which might emerge without intervention, and to identify subgroups of patients for which additional investment might be most efficiently targeted.
METHODS

Existing Literature on Value of Implementation
The proposed framework builds on existing literature on the value of implementation. 2, 7, 8, [10] [11] [12] [13] [14] [15] [16] [17] specifically the seminal study by Fenwick and others integrating value of information and value of implementation. 7 Fenwick and others 7 examined the cost-effectiveness of implementation together with value of information analysis given that, in a budget-constrained health care system, implementation activities, research, and health care interventions compete for investment. They proposed the concepts of expected value of perfect implementation (EVPIM) and expected value of specific implementation (EVSIM). EVPIM gives a measure of the maximum return to implementation activities and is a necessary condition to assess whether implementation activities are potentially worthwhile. EVSIM represents the return associated with the change in utilization achieved by specific implementation activities, the employment of which is worthwhile if EVSIM exceeds their cost. Hoomans and others 8, 12, 15 applied the concept of incremental net benefit (INB), 18 typically used to assess the value of an intervention, to implementation. They defined the INB of an implementation activity (i.e., the added benefits of an implementation activity net of its costs) as the difference between the value of improving utilization (EVSIM) and the costs of the implementation activity. Table 1 summarizes the different assessments involved in value of implementation analysis on which the extensions proposed here are built. The framework presented here extends the assessments of EVPIM and EVSIM by comparing the value of the implementation activities across different patient subgroups and explicitly accounting for changes in future utilization that could arise in the absence of additional implementation activities. The value of the implementation activity is equivalent to the total net benefit of the implementation activity by Hoomans and others. 8 The value of the implementation activity is larger the lower the costs and the higher the increase in utilization it generates. Table 1 also shows the extensions proposed here accounting for 1) multiple subgroup populations and 2) changes in future utilization.
Framework Extensions
Extension 1: Multiple Subgroups
Subgroup analysis aims to evaluate whether there is differential value in increasing utilization in specific subsets of patients, given that there may be systematic variation in the cost-effectiveness of the intervention and the subgroup size, as well as in the costs and effects of the implementation activity itself. The EVPIM for subgroup j (EVPIMj) corresponds to the number of patients in that subgroup (n j ) who are not using the cost-effective intervention (1 2 r j ), multiplied by the INB of the cost-effective intervention in that subgroup (INB j ). The increase in utilization (s j 2 r j ) may be specific to the subgroup and the cost of the implementation activity 
a. Incremental net monetary benefit used throughout for simplicity. b. If calculating in terms of health benefits, the cost of the implementation activity should be converted in its health benefit equivalent by dividing by the threshold (I/k).
(I j ) can also be specific for the subgroup. There may be leakage across subgroups in that although an implementation activity may aim to increase utilization of an intervention specifically in one subgroup, other, less valuable subgroups may also receive the intervention. This is not an issue as long as the intervention is cost-effective in these other subgroups (i.e., positive INB). The value of implementation activity will decrease if leakage occurs to subgroups in which the intervention is not costeffective.
Extension 2: Changes in Future Utilization
The second key extension relates to how utilization is likely to change in the future in the absence of implementation activities, given that some change may be expected over time without intervention. This is important because the scope for investment in implementation activities reduces as utilization increases. Ultimately, an implementation activity will not be worthwhile if utilization can be expected to increase rapidly for all indicated patients. Table 1 shows how future changes in utilization can be incorporated into value of implementation analysis. The EVPIM is the sum of 2 terms: the EVPIM for the prevalent population (i.e., the patients with the condition at the time zero),
Dr t Á INB t ); and the EVPIM in the incident patients (i.e., the patients who will develop the condition in the future), expressed as
The EVPIM for the prevalent population corresponds to the number of individuals forming the prevalent population (n P ) multiplied by the lifetime INB per patient of switching to the new intervention currently (at time zero) or at some time in the future (INB t ). (Note that INB t accounts for the patients who switched at time t and for the patients who died before the switch. This assumes that the change in utilization between t and t 2 1 in the living patients is generalizable to those who died before the switch. In other words, patients who died are assumed to have the same likelihood of switching to the new treatment as the patients who are alive.) Dr t is the proportion of the prevalent population switching medication at time t.
The EVPIM in the incident population is calculated in a similar manner. Incident patients can be given the new intervention, or they can start in the old intervention and switch to the new intervention at time t (INB t ). As with the prevalent population, Dr t represents the proportion of incident patients started or switched to the new medication at time t. The term
Þ t is the number of incident patients at time t, discounted to time zero. This is the only term requiring discounting because the INB already accounts for discounting of future costs and benefits. The calculation of EVSIM and value of implementation is similar but accounts for specific changes in utilization (Dr t 2 Ds t ) and for a cost of
Application of the Framework to a Case Study
The framework is used to evaluate the value of implementation activities in increasing the utilization of NOACs by the NHS in England and Wales. The NOACs dabigatran (Pradaxa; Boehringer Ingelheim), rivaroxaban (Xarelto; Janssen), and apixaban (Eliquis; Bristol-Myers Squibb) received a positive recommendation by NICE as alternatives to warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation with one or more risk factors. [19] [20] [21] The NOACs are an example of a class of prescription drugs recommended by NICE in its single technology appraisal process with variable and generally lower than expected uptake. 1, 22 The base case evaluates the value of implementation activities that increase the number of patients switching to NOACs. Table 2 summarizes the assumptions made and their rationale. Results are presented for a cost-effectiveness threshold of £20,000 per quality-adjusted life-year (QALY) for the NHS in England and Wales. 23 In accordance with the NICE reference case, the analysis takes the perspective of the NHS and personal social services, and future costs and health benefits are discounted at 3.5% per annum. [19] [20] [21] 23 Parameter Inputs Table 3 presents the parameter inputs used in the analysis. The INB of NOACs compared to warfarin is calculated based on the additional costs and QALYs of dabigatran as agreed on the NICE TA249 on dabigatran. 20 At the time of the analysis, NICE had reported the most plausible incremental costeffectiveness ratio only for dabigatran and did not compare each NOAC incrementally. Therefore, for
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Estimates of the population size are obtained from an audit tool used in general practice: the Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF). 24 GRASP-AF identifies patients with a diagnosis of atrial fibrillation and calculates their stroke risk based on their CHADS 2 score. The CHADS 2 score is a clinical prediction rule for estimating the risk of stroke in patients with nonvalvular atrial fibrillation. 25 GRASP-AF also highlights patients at high risk of stroke (CHADS 2 score ! 2) not receiving anticoagulation and captures this information into a national database.
The eligible population for the base case corresponds to those patients currently receiving anticoagulation (alone or in combination with antiplatelet treatment; n = 560,617 in England and Wales). Estimates of current utilization of NOACs are derived from data on the number of anticoagulant units dispensed in the community in England extrapolated to England and Wales until June 2013. 26 Overall, 3.79% of patients receiving anticoagulation are estimated to have received an NOAC in June 2013.
The effectiveness of implementation initiatives is obtained from a review of systematic reviews examining the effectiveness of activities to improve the implementation of guidelines, 4 of which 5 studies are considered applicable to the uptake of NOACs given their focus on the improved uptake of recommended medications. [27] [28] [29] [30] [31] The median absolute increase in uptake varied from 1.3% to 10.6%. The heterogeneity of the studies, both in terms on the type of intervention evaluated and outcomes, precluded quantitative synthesis. Therefore, the basecase analysis assumes that the absolute improvement in the uptake of NOACs is 5%. This corresponds to the effect of education outreach activities reported in O'Brien and others, 29 as well as in a cost-effectiveness analysis evaluating an educational activity to promote changes in prescribing practice for angiotensin-converter enzyme inhibitors and antidepressants. 10 The cost of an implementation initiative is obtained from the same cost-effectiveness study, at £284 per general practitioner (GP) practice (1999 prices). 10 These costs are inflated to a 2013 price year and extrapolated to cover all GP practices in England and Wales (n = 8729), resulting in an overall cost estimate of approximately £3.66 million.
Subgroup Analysis
The analyses conducted for the NICE TA249 on dabigatran suggested that the cost-effectiveness of NOACs may depend on the severity of the disease and on the level of warfarin control. 32 Therefore, 2 subgroup analyses are presented: 1) subgroups defined by baseline risk of stroke, as measured by CHADS 2 score, which was the risk used in the NICE Adherence to clinical guidelines is optimal: all patients indicated for anticoagulation are treated as such
The scenario tests the impact of expanding the population to all patients with a CHADS 2 score ! 2 not currently treated with anticoagulation Patients switch from warfarin to NOACs immediately following the introduction of the implementation activity and do not switch back to warfarin Follows the cost-effectiveness assessment conducted for the NICE appraisal of dabigatran
The implementation activity is an education outreach activity targeted at GPs, which increases utilization by 5% and costs £419 per GP practice
Based on the literature [27] [28] [29] [30] [31] 38 appraisal, and 2) subgroups defined by level of warfarin control (good v. poor to average control). Table  3 shows the parameter inputs for the subgroup analysis and their sources. Details are presented in the Appendix. The subgroup analysis assumes that the current utilization of NOACs, the increase in utilization generated by the implementation activities, and the cost of those activities in these subgroups are the same as in the base case. Because the implementation activity is aimed at GPs rather than individual patients, its cost depends on the number of GPs contacted and should remain the same regardless of how many patients are affected. The impact of these assumptions is explored in the threshold analysis.
The Impact of an Increase in Utilization in the Future
Even without explicit implementation activities, the utilization of NOACs is likely to increase over time as clinicians become more knowledgeable about these drugs, as more evidence on their effectiveness and safety emerges, and as patient awareness increases. The impact of an increase in future utilization on the scope for investment in implementation is shown using a time horizon for the implementation activity of 5 years.
Future utilization between 2014 and 2018 is predicted using 2 regression models fitted to the proportion of patients taking NOACs between June 2011 (dabigatran market entry) and June 2013 (time of data collection): 1) a model in which utilization changes linearly with time; and 2) a quadratic model in which utilization changes linearly with time and with the square of time (see Appendix for details). Both models fitted the observed data well and predicted that utilization would increase over time. The predicted rate of change is greater for the polynomial model, which predicts that utilization reaches 80% by 2018, whereas the linear model predicts a utilization at 14% by that date. As such, these alternative models lead to 2 analyses with wide-ranging estimates of future uptake.
As discussed earlier, calculating the value of implementation over time involves data not only on future utilization but also on the lifetime INB accounting for delays in treatment switch from warfarin to NOACs. Although it was not possible to access or rebuild the cost-effectiveness model used in the NICE TA249 on dabigatran, the impact of a delay in treatment switch on the INB can be approximated by assuming that the INB is accrued linearly over time (i.e., by dividing the INB over remaining life expectancy of the patient cohort). However, in long-term treatments for chronic diseases, the annual INB is likely to take a parabolic shape: negative as treatment costs outweigh the benefits, positive as the treatment prevents adverse health outcomes, and negative again as the mortality risk from other causes increases. Despite this limitation, it demonstrates the impact of future utilization on the current value of NOACs for the NHS and on the scope for investment in implementation. 
Threshold Analysis
The cost and increase in utilization achieved by the implementation activity may differ depending on whether the entire population or specific subgroups are targeted. Therefore, a threshold sensitivity analysis is presented showing the combination of the maximum cost of the implementation activity and specific increases in utilization that are consistent with that activity being cost-effective. This is applied to the entire population, the subgroup with CHADS 2 scores 5 and 6, and the subgroup with poor to average warfarin control.
Scenario Analysis
The scenario analysis explores the impact of alternative warfarin monitoring costs (scenario 1) and of increasing anticoagulation with warfarin or NOACs in patients who are potentially eligible but are not currently taking aspirin or are receiving no treatment (scenario 2). Table 3 also shows the parameter inputs for the scenario analysis and their sources. Details are presented in the Appendix. The rationale for scenario 1 is that warfarin monitoring costs may vary widely across different localities. Therefore, at a local level, there may be more or less scope for investment in activities to increase utilization depending on the costs of warfarin monitoring. This uncertainty was recognized in NICE TA249 on dabigatran, 20 and the NICE costing template tested the impact of varying costs by 20% (from the base case of £242 per patient per year to £193 or £290). 33, 34 Scenario 2 addresses the issue that more than half a million patients with atrial fibrillation in the United Kingdom are not treated consistently with clinical guidelines, in that they are not using anticoagulation. 24 Although some patients may be contraindicated or refuse treatment, most would stand to benefit from anticoagulation. 35 
RESULTS
Base Case: Value of Implementation in Patients Currently Taking Warfarin
The EVPIM, at £97.63 million or 4882 QALYs, represents the maximum amount that the NHS could invest in implementation activities while still accruing some value from the intervention itself (NOACs). This represents the potential value of NOACs in the eligible population currently not using these drugs and who instead still currently receive warfarin for anticoagulation. The EVSIM, at £5.08 million or 254 QALYs, represents the maximum amount that the NHS should invest for an increase in utilization of 5% (from 3.79% to 8.79%). The value of the implementation activity represents its additional value given its expected cost. An implementation activity increasing utilization by 5% (base case) and costing an average of £419 per GP practice adds additional value to the NHS of £1.42 million or 71 QALYs for England and Wales. Figure 1 shows the value of implementation for the entire (base case) and subgroup populations. In the subgroups defined by CHADS 2 score, EVPIM ranged between £17.4 million and £26.1 million and EVSIM between £0.9 million and £1.4 million (compared with £97.6 million and £5.1 million in the entire population). Therefore, if the costs of the implementation activity for each subgroup are in the same order of magnitude (i.e., £3.66 million) as for the entire patient population, then additional implementation activity would not be worthwhile if restricted to specific CHADS 2 scores. In contrast, the value of implementation is much increased in the subgroup with average or poor warfarin control. This is the result of the combined effect of the greater value of NOACs in the subgroups (INB £925 v. £181) and the large proportion of the population standing to benefit (n = 420,463), which is greater than the number of patients in the most severe CHADS 2 subgroup (CHADS 2 scores 5 and 6, n = 22,993). Therefore, by targeting implementation efforts in the subgroup population with average or poor warfarin control, the NHS would stand to gain more value than in trying to increase utilization equally across the entire population.
Subgroup Analysis
The Impact of an Increase in Utilization in the Future increases. The current value of NOACs to the NHS is £4.8 million. As more patients are switched from warfarin to NOACs, the current value increases. Over 5 years, the current value is £10.5 million using the linear model and £49.0 million using the polynomial model. The bars in white represent the EVPIM over time. The EVPIM decreases over a 5year time horizon from £97.6 million in the base case to £91.0 million using the linear model and to £52.5 million using the polynomial model. Figure 3 shows the combination of the maximum cost of the implementation activity and specific increases in utilization that are consistent with that activity being cost-effective. The investment increases linearly with the increase in utilization. In the base-case population, a 1% increase in utilization warrants up to £1 million investment across England and Wales. In the subgroup with CHADS 2 scores 5 and 6, the investment per 1% increase in utilization is much smaller, at approximately £270,000. Unless cost of the implementation activity is substantially smaller than in the base case, its deployment is not worthwhile if it targets solely this subgroup. Conversely, a 1% increase in utilization in the subgroup with poor to average warfarin control warrants up to £3.9 million in investment. Figure 4 shows the results of the scenario analysis and the base case for comparison. In scenario 1, at higher warfarin monitoring costs, the INB increases and so does the value of implementation. The EVSIM for an increase of 5% in uptake is £14 million (704 QALYs) for a warfarin monitoring cost of £290 per patient per year; hence, the NHS could invest up to £14 million in implementation activities and still accrue some value from NOACs. Scenario 2 takes the population with atrial fibrillation and a CHADS 2 score ! 2 who are using antiplatelets or are receiving no intervention for the prevention of stroke and systemic embolism who are not contraindicated for or who did not refuse anticoagulation (n = 242,336). The value of implementation is much greater for switching these patients to an anticoagulant than for switching from warfarin to NOACs. For example, the EVPIM is £1,135 million for the comparison of warfarin v. aspirin compared with £97.6 million in the base case. The EVSIM, which shows the maximum the NHS can invest in switching patients to the costeffective intervention, is £99.8 million for an activity that increases utilization by 5%. This suggests that there is greater scope to invest in implementation activities for patients receiving antiplatelet or no treatment than for switching patients between anticoagulants.
Threshold Analysis
Scenario Analysis
DISCUSSION Principal Findings
This study presents a conceptual framework to estimate the potential and actual value of implementation activities to improve the utilization of of implementation analysis to inform policy and indicates the issues and challenges in applying this framework in practice.
This case study suggests that there is value in additional implementation efforts directed toward encouraging the utilization of NOACs. This additional value can be represented both in terms of net health and monetary benefits to the NHS. At a cost-effectiveness threshold of £20,000 per QALY gained, an additional £3.66 million in investment in an activity that increases utilization by 5% would generate an additional 71 QALYs (£1.42 million in terms of monetary equivalent) across England and Wales compared with the use of these resources in other (health-generating) NHS activities. The value of implementation appears highest in targeting efforts to increase the utilization of NOACs in patients with average to poor warfarin control. In contrast, there appears to be no value in investing in increasing utilization in more severe CHADS 2 subgroups. Although NOACs had a more favorable cost-effectiveness profile per patient in the more severe subgroups, the smaller size of this subgroup means that the benefits of treatment are outweighed by the cost of an implementation activity. However, this assumes that the cost of the implementation activity is unrelated to the size of the patient population but instead depends on the number of health care professionals involved. This is plausible for the type of education activity assumed here but may not be the case for all types of intervention. In addition, the investment in implementation activities may depend on local constraints (e.g., warfarin monitoring costs) or other factors that can have an impact on the cost-effectiveness of the intervention. This may also raise ethical concerns, in that investment in the implementation of an intervention for a larger subgroup may generate greater gains in population health despite a change in utilization generating fewer gains in outcomes per patient than in a smaller subgroup. Importantly, greater value to the NHS would potentially be achieved with higher uptake of anticoagulation more generally (i.e., including warfarin), given the high proportion of individuals with atrial fibrillation who are currently receiving no treatment or antiplatelet therapy only.
Strengths and Limitations
This study extends the value of implementation framework to account for multiple subgroups and for changes in utilization in the future. The framework and its application directly inform decisions that health care managers have to make on how to invest appropriately in implementation activities associated with NICE's recommended technologies in general and NOACs in particular. It shows that there is scope to invest in the implementation of NOACs, but the investment offers better returns if targeted to patients with poor to average warfarin control and eligible patients who are receiving aspirin or no treatment. The estimates were obtained from publically available data, published literature, and NICE recommendations. The lack of access to cost-effectiveness estimates for subgroups and scenarios was addressed through innovative derivation of INB from the available data. Although estimated INBs for delays in treatment initiation were not available, the impact of changes in future utilization on the value of implementation is presented through an illustration.
There are, however, limitations to the analysis. The NICE appraisals did not report cost-effectiveness results for rivaroxaban and apixaban, nor for subgroups and scenarios under the committee's preferred assumptions. Furthermore, the cost-effectiveness model was not available in order to obtain the lifetime INB for delays in the switch between treatments. Therefore, the INBs required were derived from the available inputs and may not accurately represent the cost-effectiveness of each NOAC for each subgroup and scenario. There was also limited evidence on the effectiveness of alternative implementation activities to this specific case study. Consequently, it has not been possible to provide a comprehensive analysis comparing the cost-effectiveness of alternative implementation activities. Nonetheless, the threshold analysis shows the level of uptake that would be required per British pound spent by the NHS or other health care systems in order for an implementation activity to be cost-effective, which can be applied to a broader range of potential implementation activities.
Uncertainties and Future Research
The key remaining uncertainty relates to future utilization with and without implementation activities. This involves predicting future utilization in the absence of implementation activities on the basis of historical data and extrapolating the increase in utilization from specific implementation activities. Despite the extensive literature on implementation activities, 4 little is known on their
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ORIGINAL ARTICLE generalizability of other situations and how best to tackle the different barriers to implementation. In this case study, anecdotal reports suggest that the barriers to implementation may be more related to concerns around the budget impact in primary care while potential savings are in secondary care, rather than the clinicians' lack of experience in the use of NOACs. These may require other types of activities in addition to the educational outreach activity used in the case study, such as budget transfers between sectors.
More research is also required on the impact of uncertainty on the scope for investment in implementation and its interaction with the value of information. Fenwick and others showed how imperfect implementation affects the value of future research. 7 A recent study extended this further by accounting for different degrees of implementation. 36 Uncertainty may affect implementation in that the investment in implementation activities should reflect the cost of uncertainty around the decision. Therefore, and all things equal, investment in interventions highly likely to be cost-effective should be greater than in more uncertain interventions.
Implications for Policy
This study presents a framework to evaluate the value of implementation activities following the cost-effectiveness assessment of the intervention. Although, in principle, the 2 could be conducted simultaneously, this separation avoids conflating 2 separate concepts: 1) the value of the intervention itself, and potential population net benefit assuming perfect implementation; and 2) the value of any specific implementation activities, and the achievable net benefits. It allows for the evaluation of implementation activities that respond to specific challenges in getting the interventions into practice, which became apparent only ex post. The framework helps to highlight the potential magnitude of population net benefit that could be realized (in a perfect world) and the magnitude of acceptable investment on specific implementation activities.
This case study shows that value of implementation is most useful in policy for wider definitions of the decision problem. Although the new intervention should be compared against all other potential cost-effective options in cost-effectiveness analysis, value of implementation should include interventions that are known not to be cost-effective but are still used in current practice. Including aspirin and no treatment shows that the benefits of investing in activities that promote switching patients from aspirin or no treatment to anticoagulation are much greater than switching between anticoagulants. The focus on the comparison of NOACs v. warfarin risks ignoring the value of increasing anticoagulation more generally. It can reinforce the ''adoption'' mentality by which new drugs that are more beneficial but also more expensive are given priority for implementation investments. 37 There is, however, a wider policy question in the diagnosis and management of patients with atrial fibrillation. Again, value of implementation can be used to inform the question of where to prioritize efforts to improve implementation of existing evidence-based guidelines across the full care pathway or across populations in different disease areas. More generally, value of implementation can help health services compare the costs and benefits of investing resources in improving the utilization of cost-effective technologies, consistent with the value assessment of new interventions. 11. Sculpher M. Evaluating the cost-effectiveness of interventions designed to increase the utilization of evidence-based guidelines. Fam Pract. 2000;17:S26-31.
